Abstract
Background & Aims: A single nucleotide polymorphism 61 (*)G (rs4444903) in the epidermal growth factor (EGF) gene has been associated, in 2 case-control studies, with hepatocellular carcinoma (HCC). We tested associations between demographic, clinical, and genetic data and development of HCC, and developed a simple predictive model in a cohort of patients with chronic hepatitis C and advanced fibrosis. Methods: Black and white subjects from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial (n = 816) were followed up prospectively for development of a definite or presumed case of HCC for a median time period of 6.1 years. We used the Cox proportional hazards regression model to determine the hazard ratio for risk of HCC and to develop prediction models. Results: Subjects with EGF genotype G/G had a higher adjusted risk for HCC than those with genotype A/A (hazard ratio, 2.10; 95% confidence interval, 1.054.23; P =.03). After adjusting for EGF genotype, blacks had no increased risk of HCC risk compared with whites. Higher serum levels of EGF were observed among subjects with at least one G allele (P =.08); the subset of subjects with EGF G/G genotype and above-median serum levels of EGF had the highest risk of HCC. We developed a simple prediction model that included the EGF genotype to identify patients at low, intermediate, and high risk for HCC; 6-year cumulative HCC incidences were 2.3%, 10.4%, and 26%, respectively. Conclusions: We associated the EGF genotype G/G with increased risk for HCC; differences in its frequency among black and white subjects might account for differences in HCC incidence between these groups. We developed a model that incorporates EGF genotype and demographic and clinical variables to identify patients at low, intermediate, and high risk for HCC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 141-149 |
| Number of pages | 9 |
| Journal | Gastroenterology |
| Volume | 141 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 2011 |
| Externally published | Yes |
Fingerprint
Keywords
- Cancer
- HCV
- Liver Disease
- Prognosis
- Tumor
ASJC Scopus subject areas
- Gastroenterology
Cite this
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. / Abu Dayyeh, Barham K.; Yang, May; Fuchs, Bryan C.; Karl, Daniel L.; Yamada, Suguru; Sninsky, John J.; O'Brien, Thomas R.; Dienstag, Jules L.; Tanabe, Kenneth K.; Chung, Raymond T.
In: Gastroenterology, Vol. 141, No. 1, 07.2011, p. 141-149.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma
AU - Abu Dayyeh, Barham K.
AU - Yang, May
AU - Fuchs, Bryan C.
AU - Karl, Daniel L.
AU - Yamada, Suguru
AU - Sninsky, John J.
AU - O'Brien, Thomas R.
AU - Dienstag, Jules L.
AU - Tanabe, Kenneth K.
AU - Chung, Raymond T.
PY - 2011/7
Y1 - 2011/7
N2 - Background & Aims: A single nucleotide polymorphism 61 (*)G (rs4444903) in the epidermal growth factor (EGF) gene has been associated, in 2 case-control studies, with hepatocellular carcinoma (HCC). We tested associations between demographic, clinical, and genetic data and development of HCC, and developed a simple predictive model in a cohort of patients with chronic hepatitis C and advanced fibrosis. Methods: Black and white subjects from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial (n = 816) were followed up prospectively for development of a definite or presumed case of HCC for a median time period of 6.1 years. We used the Cox proportional hazards regression model to determine the hazard ratio for risk of HCC and to develop prediction models. Results: Subjects with EGF genotype G/G had a higher adjusted risk for HCC than those with genotype A/A (hazard ratio, 2.10; 95% confidence interval, 1.054.23; P =.03). After adjusting for EGF genotype, blacks had no increased risk of HCC risk compared with whites. Higher serum levels of EGF were observed among subjects with at least one G allele (P =.08); the subset of subjects with EGF G/G genotype and above-median serum levels of EGF had the highest risk of HCC. We developed a simple prediction model that included the EGF genotype to identify patients at low, intermediate, and high risk for HCC; 6-year cumulative HCC incidences were 2.3%, 10.4%, and 26%, respectively. Conclusions: We associated the EGF genotype G/G with increased risk for HCC; differences in its frequency among black and white subjects might account for differences in HCC incidence between these groups. We developed a model that incorporates EGF genotype and demographic and clinical variables to identify patients at low, intermediate, and high risk for HCC.
AB - Background & Aims: A single nucleotide polymorphism 61 (*)G (rs4444903) in the epidermal growth factor (EGF) gene has been associated, in 2 case-control studies, with hepatocellular carcinoma (HCC). We tested associations between demographic, clinical, and genetic data and development of HCC, and developed a simple predictive model in a cohort of patients with chronic hepatitis C and advanced fibrosis. Methods: Black and white subjects from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial (n = 816) were followed up prospectively for development of a definite or presumed case of HCC for a median time period of 6.1 years. We used the Cox proportional hazards regression model to determine the hazard ratio for risk of HCC and to develop prediction models. Results: Subjects with EGF genotype G/G had a higher adjusted risk for HCC than those with genotype A/A (hazard ratio, 2.10; 95% confidence interval, 1.054.23; P =.03). After adjusting for EGF genotype, blacks had no increased risk of HCC risk compared with whites. Higher serum levels of EGF were observed among subjects with at least one G allele (P =.08); the subset of subjects with EGF G/G genotype and above-median serum levels of EGF had the highest risk of HCC. We developed a simple prediction model that included the EGF genotype to identify patients at low, intermediate, and high risk for HCC; 6-year cumulative HCC incidences were 2.3%, 10.4%, and 26%, respectively. Conclusions: We associated the EGF genotype G/G with increased risk for HCC; differences in its frequency among black and white subjects might account for differences in HCC incidence between these groups. We developed a model that incorporates EGF genotype and demographic and clinical variables to identify patients at low, intermediate, and high risk for HCC.
KW - Cancer
KW - HCV
KW - Liver Disease
KW - Prognosis
KW - Tumor
UR - http://www.scopus.com/inward/record.url?scp=79959996152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959996152&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2011.03.045
DO - 10.1053/j.gastro.2011.03.045
M3 - Article
C2 - 21440548
AN - SCOPUS:79959996152
VL - 141
SP - 141
EP - 149
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 1
ER -